☆ 4.7 Article

Antibody and T-Cell Subsets Analysis Unveils an Immune Profile Heterogeneity Mediating Long-term Responses in Individuals Vaccinated Against SARS-CoV-2

JOURNAL OF INFECTIOUS DISEASES (2023)

Related references

Note: Only part of the references are listed.

Article Cell Biology

Kinetics and persistence of cellular and humoral immune responses to SARS-CoV-2 vaccine in healthcare workers with or without prior COVID-19

Mihaela Chivu-Economescu et al.

Summary: SARS-CoV-2 vaccines are effective in preventing severe forms of the disease, hospitalization, and death. However, they may provide insufficient protection against certain viral variants, indicating the need for additional vaccine doses. A study found that even after 6 months of vaccination or infection, the neutralizing activity remains high, although there is a slight decrease in the level of anti-S IgG antibodies. Vaccinated individuals who had a prior infection showed the highest neutralization titres. The study also observed cellular immune responses in vaccinated participants, even in those with declining antibody levels or low neutralizing activity, although the response was lower compared to those with preserved humoral responses.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2022)

Add to Collection

Article Multidisciplinary Sciences

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Peter B. Gilbert et al.

Summary: In the COVE phase 3 clinical trial, neutralizing and binding antibodies were measured in vaccine recipients to determine their correlation with COVID-19 risk and vaccine efficacy. The results showed that these immune markers were inversely associated with COVID-19 risk and directly associated with vaccine efficacy. Postvaccination neutralization titers of 10, 100, and 1000 correlated with estimated vaccine efficacies of 78%, 91%, and 96% respectively.

SCIENCE (2022)

Add to Collection

Article Cell Biology

Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19

Roberto Lozano-Rodriguez et al.

Summary: Our study shows that individuals recovered from COVID-19 only need one vaccine shot to generate high levels of immune responses, while naive subjects require two doses. However, both groups show comparable neutralizing antibodies and S-specific B cell levels in the late post-vaccination period. In terms of cellular responses, naive individuals exhibit higher levels of immune cell activation and proliferation compared to individuals recovered from COVID-19 in the early post-vaccination period, but after almost 8 months post-vaccination, both groups have comparable cellular responses.

CELL REPORTS (2022)

Add to Collection

Article Immunology

High-affinity, neutralizing antibodies to SARS-CoV-2 can be made without T follicular helper cells

Jennifer S. Chen et al.

Summary: This study found that both T-FH-dependent and -independent antibodies were induced against SARS-CoV-2 infection, vaccination, and influenza A virus infection. The T-FH-independent antibodies had reduced somatic hypermutation but were still high affinity and capable of neutralizing diverse spike-derived epitopes and variants of concern.

SCIENCE IMMUNOLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222

Evangelos Terpos et al.

Summary: This study compared the neutralizing antibody levels after vaccination with BNT162b2 mRNA vaccine and ChAdOx1 (AZD1222) viral vector vaccine at different time points. The results showed that BNT162b2 induced stronger neutralizing antibody responses compared to AZD1222, and both vaccines showed a gradual decline in antibody titers over time. Additionally, the rate of antibody elimination was higher in those vaccinated with AZD1222 compared to BNT162b2. Age, gender, body mass index, or comorbidities did not significantly impact antibody levels over time.

BIOMEDICINES (2022)

Add to Collection

Article Immunology

Lack of Induction of RBD-Specific Neutralizing Antibodies despite Repeated Heterologous SARS-CoV-2 Vaccination Leading to Seroconversion and Establishment of T Cell-Specific Memory in a Patient in Remission of Multiple Myeloma

Bernhard Kratzer et al.

Summary: Immunocompromised patients may have a poor response to SARS-CoV-2 vaccination, requiring adjustment of vaccination schedules and therapy. This study vaccinated a patient with multiple myeloma and observed no signs of immune response after the first vaccine, but positive immune response after subsequent vaccination.

VACCINES (2022)

Add to Collection

Article Multidisciplinary Sciences

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Jennifer M. Dan et al.

Summary: Different components of immune memory to SARS-CoV-2 exhibit distinct kinetics, with antibodies and spike-specific memory B cells remaining relatively stable over 6 months, while CD4(+) T cells and CD8(+) T cells declining with a half-life of 3 to 5 months after infection.

SCIENCE (2021)

Add to Collection

Article Cell Biology

Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients

Anthony T. Tan et al.

Summary: This study found that early induction of interferon-gamma (IFN-gamma) secreting SARS-CoV-2-specific T cells was present in patients with mild disease and accelerated viral clearance, while rapid induction and quantity of humoral responses were associated with an increase in disease severity. These findings highlight the importance of early functional SARS-CoV-2-specific T cells in both vaccine design and immune monitoring.

CELL REPORTS (2021)

Add to Collection

Article Medicine, General & Internal

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine

Ann R. Falsey et al.

Summary: The clinical trial in the United States, Chile, and Peru showed that the AZD1222 vaccine was both safe and effective in preventing symptomatic and severe Covid-19 cases, with an overall estimated efficacy of 74% and a higher efficacy of 83.5% in participants 65 years of age or older. The high vaccine efficacy was consistent across various demographic subgroups, and antibodies increased significantly after each dose.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

Einav G. Levin et al.

Summary: A study in Israel revealed that waning immunity after receiving two doses of the BNT162b2 vaccine led to an increase in the incidence of SARS-CoV-2 infection. Levels of spike-binding IgG and neutralizing antibodies decreased more significantly in men, individuals aged 65 or older, and immunosuppressed individuals in a longitudinal study involving nearly 4000 healthcare workers.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Immunology

Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection

Nina Le Bert et al.

Summary: The efficacy of virus-specific T cells in clearing pathogens involves a delicate balance between antiviral and inflammatory responses. Asymptomatic individuals clearing SARS-CoV-2 showed increased production of IFN-gamma and IL-2, along with a proportional secretion of IL-10 and proinflammatory cytokines, while symptomatic individuals displayed a disproportionate secretion of inflammatory cytokines triggered by SARS-CoV-2-specific T cell activation.

JOURNAL OF EXPERIMENTAL MEDICINE (2021)

Add to Collection

Article Immunology

Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection

Jianmin Zuo et al.

Summary: The study shows that functional SARS-CoV-2-specific T cell responses are retained and robust at 6 months following infection, with higher T cell responses observed in donors who had experienced symptomatic infection. Levels of nucleoprotein-specific T cells were correlated with nucleoprotein-specific antibody levels, providing insights into the persistence and correlation of immune responses.

NATURE IMMUNOLOGY (2021)

Add to Collection

Letter Hematology

Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine

Evangelos Terpos et al.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Add to Collection

Article Immunology

BNT162b2 vaccination induces durable SARS-CoV-2-specific T cells with a stem cell memory phenotype

Gisella Guerrera et al.

Summary: Vaccination with the Pfizer-BioNTech mRNA vaccine induces a sustained anti-viral T cell response for at least 6 months, demonstrating immunological competence and long-term memory against SARS-CoV-2.

SCIENCE IMMUNOLOGY (2021)

Add to Collection

Article Infectious Diseases

Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study

Cristina Menni et al.

Summary: This study investigated the safety and effectiveness of the BNT162b2 and ChAdOx1 nCoV-19 vaccines in a UK community setting. The results showed that the frequencies of side effects from these vaccines were lower than reported in clinical trials, and a significant reduction in the risk of SARS-CoV-2 infection was observed starting at 12 days after vaccination.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

David S. Khoury et al.

Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.

NATURE MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

Nicole Doria-Rose et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Infectious Diseases

Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan

Takahiro Kageyama et al.

Summary: The study aimed to determine antibody responses in healthcare workers following the BNT162b2 mRNA COVID-19 vaccine and identified factors that predict the response. Results showed that healthcare workers have good antibody responses to the vaccine, with factors like immunosuppressive medication, age, and time from vaccination affecting antibody titers.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

Add to Collection

Article Multidisciplinary Sciences

Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2

Dami A. Collier et al.

Summary: Elderly individuals, especially those above eighty, show lower immune responses and neutralization abilities against variants of concern after the first vaccine dose, but this improves after the second dose. They have higher frequencies of spike-specific memory B cells but reduced somatic hypermutation of class-switched cells. Production of interferon-gamma and interleukin-2 by SARS-CoV-2 spike-specific T cells is lower in older participants, predominantly by CD4 T cells.

NATURE (2021)

Add to Collection

Letter Medicine, General & Internal

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3

Ann R. Falsey et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants

Amarendra Pegu et al.

Summary: The study assessed the impact of SARS-CoV-2 variants on antibody responses induced by the mRNA vaccine over 7 months, showing that most individuals maintained binding and functional antibodies against variants, with B.1.351 having the lowest antibody recognition.

SCIENCE (2021)

Add to Collection

Article Multidisciplinary Sciences

Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells

Jose Mateus et al.

Summary: This study examined the immune responses to the Moderna mRNA-1273 vaccine over 7 months, finding that subjects with preexisting cross-reactive T cell memory exhibited stronger CD4(+) T cell and antibody responses to the vaccine. This demonstrates the biological relevance and potential importance of cross-reactive T cells in generating immunity to SARS-CoV-2.

SCIENCE (2021)

Add to Collection

Article Immunology

Evidence for antibody as a protective correlate for COVID-19 vaccines

Kristen A. Earle et al.

Summary: The study found a strong correlation between antibody titers and efficacy when assessing different COVID-19 vaccines, supporting the use of post-immunization antibody titers as the basis for establishing a correlate of protection for COVID-19 vaccines.

VACCINE (2021)

Add to Collection

Article Immunology

mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects

Dorit Fabricius et al.

Summary: The study found that mRNA vaccines induced stronger cellular and serological immune responses, including neutralizing capacity against VOCs, compared to ChAdOx1-nCoV-19. Booster immunizations with mRNA vaccines triggered strong and broadly neutralizing antibody and IFN-gamma responses in 100% of vaccinated individuals, especially for those with prior COVID-19 or ChAdOx1-nCoV-19 vaccination.

VACCINES (2021)

Add to Collection

Article Immunology

Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination

Lisa Mueller et al.

Summary: The study compared antibody responses to the BNT162b2 COVID-19 vaccine in young vaccinees below 60 and elderly vaccinees over 80. The elderly group had lower antibody titers and a lower frequency of neutralizing antibodies post-vaccination, indicating a potential need for closer monitoring or different vaccination strategies for this population.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Health Care Sciences & Services

Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study

Paul Naaber et al.

Summary: The study found that antibody levels declined at 12 weeks and 6 months after receiving two doses of BNT162b2 vaccine, with Spike antibody levels at 6 months being similar to those in individuals who received one dose or had recovered from COVID-19. Most individuals developed Spike-specific memory T cell responses, which were lower in those with higher T cell immunosenescence. Antibody response was negatively correlated with age and positively correlated with the total score of vaccination side effects.

LANCET REGIONAL HEALTH-EUROPE (2021)

Add to Collection

Article Cell Biology

Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection

Arunasingam Abayasingam et al.

Summary: The study suggests that while neutralizing antibodies in plasma may decline, the neutralizing capacity can still be maintained in the memory B cell repertoire. These memory B cells are capable of continuously producing antibodies with neutralizing capacity against SARS-CoV-2.

CELL REPORTS MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

Takuya Sekine et al.

CELL (2020)

Add to Collection

Article Multidisciplinary Sciences

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Ugur Sahin et al.

NATURE (2020)

Add to Collection

Article Medicine, General & Internal

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Immunology

SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation

Katlyn Lederer et al.

IMMUNITY (2020)

Add to Collection

Article Medicine, Research & Experimental

SARS-CoV-2-specific T cell responses and correlations with COVID-19 patient predisposition

Arne Sattler et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

Add to Collection

Review Immunology

Helper T cell differentiation

Jordy Saravia et al.

CELLULAR & MOLECULAR IMMUNOLOGY (2019)

Add to Collection

Article Immunology

Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses

Norbert Pardi et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2018)

Add to Collection

Article Immunology

Induction of Robust B Cell Responses after Influenza mRNA Vaccination Is Accompanied by Circulating Hemagglutinin-Specific ICOS+ PD-1+CXCR3+T Follicular Helper Cells

Gustaf Lindgren et al.

FRONTIERS IN IMMUNOLOGY (2017)

Add to Collection

Article Immunology

Higher numbers of memory B-cells and Th2-cytokine skewing in high responders to hepatitis B vaccination

A. M. C. M. Doedee et al.

VACCINE (2016)

Add to Collection

Review Biotechnology & Applied Microbiology

Primary vaccine failure to routine vaccines: Why and what to do?

Ursula Wiedermann et al.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)

Add to Collection

Article Immunology

Tick-Borne Encephalitis (TBE) and Hepatitis B Nonresponders Feature Different Immunologic Mechanisms in Response to TBE and Influenza Vaccination with Involvement of Regulatory T and B Cells and IL-10

Erika Garner-Spitzer et al.

JOURNAL OF IMMUNOLOGY (2013)

Add to Collection

Article Immunology

Hepatitis B vaccination: A completed schedule enough to control HBV lifelong? Milan, Italy, 17-18 November 2011

David FitzSimons et al.

VACCINE (2013)

Add to Collection

Article Immunology

High-Dimensional Gene Expression Profiling Studies in High and Low Responders to Primary Smallpox Vaccination

Iana H. Haralambieva et al.

JOURNAL OF INFECTIOUS DISEASES (2012)

Add to Collection

Article Immunology

T cell responses to whole SARS coronavirus in humans

Chris Ka-fai Li et al.

JOURNAL OF IMMUNOLOGY (2008)

Add to Collection

Review Immunology

T-cell quality in memory and protection: implications for vaccine design

Robert A. Seder et al.

NATURE REVIEWS IMMUNOLOGY (2008)

Add to Collection

Article Immunology

Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants

D FitzSimons et al.

VACCINE (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.